Literature DB >> 29030645

No, we are not-we keep forgetting the right ventricle.

Victoria C Ziesenitz1,2, Walter E Haefeli3, Johannes N van den Anker4, Matthias Gorenflo5.   

Abstract

Mesh：

Year:  2017        PMID： 29030645     DOI： 10.1007/s00228-017-2349-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  23 in total

Review 1.  Perspective on the optimal endpoints for pulmonary arterial hypertension trials.

Authors:  Lewis Rubin; Gérald Simonneau
Journal:  Curr Opin Pulm Med       Date:  2010-05       Impact factor: 3.155

2.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  Acute effect of sildenafil on central hemodynamics in mechanically ventilated patients with WHO group III pulmonary hypertension and right ventricular failure necessitating administration of dobutamine.

Authors:  Dimitrios Karakitsos; John Papanikolaou; Andreas Karabinis; Raed Alalawi; Mitchell Wachtel; Cynthia Jumper; Dimitrios Alexopoulos; Periklis Davlouros
Journal:  Int J Cardiol       Date:  2012-03-03       Impact factor: 4.164

4.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

5.  Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.

Authors:  Gianluigi Savarese; Stefania Paolillo; Pierluigi Costanzo; Carmen D'Amore; Milena Cecere; Teresa Losco; Francesca Musella; Paola Gargiulo; Caterina Marciano; Pasquale Perrone-Filardi
Journal:  J Am Coll Cardiol       Date:  2012-09-25       Impact factor: 24.094

6.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

Authors:  S Miyamoto; N Nagaya; T Satoh; S Kyotani; F Sakamaki; M Fujita; N Nakanishi; K Miyatake
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

7.  Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.

Authors:  Vallerie McLaughlin; Richard N Channick; Hossein-Ardeschir Ghofrani; Jean-Christophe Lemarié; Robert Naeije; Milton Packer; Rogério Souza; Victor F Tapson; Jonathan Tolson; Hikmet Al Hiti; Gisela Meyer; Marius M Hoeper
Journal:  Eur Respir J       Date:  2015-06-25       Impact factor: 16.671

Review 8.  Sildenafil for pulmonary hypertension.

Authors:  P Kanthapillai; Tj Lasserson; Eh Walters
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 9.  Endothelin receptor antagonists for pulmonary arterial hypertension.

Authors:  Chao Liu; Junmin Chen; Yanqiu Gao; Bao Deng; Kunshen Liu
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

10.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.